Related Experiment Video
Updated: Mar 23, 2026
07:37
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
1.4K
Targeting Syk in Autoimmune Rheumatic Diseases
Guo-Min Deng1, Vasileios C Kyttaris2, George C Tsokos2
1Key Laboratory of Antibody Techniques of Ministry of Health, Nanjing Medical University, Nanjing, China; State Key Laboratory of Reproductive Medicine, Nanjing Medical University, Nanjing, China.
Frontiers in Immunology
|March 26, 2016
Summary
Spleen tyrosine kinase (Syk) inhibitors show promise in treating autoimmune diseases like rheumatoid arthritis and lupus. While effective, potential side effects require careful consideration for patient safety.
Area of Science:
- Immunology
- Molecular Biology
- Pharmacology
Background:
- Spleen tyrosine kinase (Syk) is a key signaling molecule in immune cells.
- Syk mediates signal transduction pathways crucial for immune responses.
- Autoimmune diseases like rheumatoid arthritis (RA) and systemic lupus erythematosus involve aberrant immune cell activity.
Purpose of the Study:
- To review the therapeutic potential of Syk inhibitors in autoimmune diseases.
- To evaluate the efficacy of Syk inhibition in preclinical models and human patients.
- To discuss the benefits and drawbacks of using Syk inhibitors for autoimmune conditions.
Main Methods:
- Literature review of studies on Syk inhibitors in autoimmune diseases.
- Analysis of preclinical data from mouse models of RA and lupus.
- Examination of clinical trial data and patient outcomes for Syk inhibitor treatment.
Main Results:
- Syk inhibitors effectively suppress disease activity in rheumatoid arthritis patients.
- Syk inhibitors demonstrate efficacy in inhibiting clinical manifestations in lupus-prone mice.
- Reported side effects of Syk inhibitors include gastrointestinal issues, hypertension, and neutropenia.
Conclusions:
- Syk inhibitors represent a promising therapeutic strategy for autoimmune diseases.
- Further research is warranted to optimize Syk inhibitor therapy and manage side effects.
- Targeting Syk offers a potential pathway for treating immune-mediated inflammatory conditions.
Related Concept Videos
01:20The JAK-STAT Signaling Pathway
13.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
13.8K
01:29Autoimmune Disorders
2.1K
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
2.1K
01:27Transducer Mechanism: Enzyme-Linked Receptors
4.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
4.8K
01:24T Cell Types and Functions
3.2K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.2K
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
66
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
66
02:57Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K